Stock listing
NASDAQ:SPRY ARS Pharmaceuticals, Inc. Stock
Home listing (NASDAQ) of ARS Pharmaceuticals, Inc.
Follow ARS Pharmaceuticals, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:SPRY
$2.96 USD -0.73 (-19.8%)
Close on Nov 20, 2026
- Day range
- $2.86 – $3.47 USDNov 20, 2026
- Volume
- 2.78M sharesNov 20, 2026
- Market cap
- $297.6M USDAt the close on Nov 20, 2026 · price × 100.5M shares outstanding
- 52-week range
- $2.44 – $13.15 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $7.42M USDMedian day 1.58M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:SPRY · Home | $2.96 USD | -0.73 (-19.8%) | 2,784,259 | $3.28 | $3.465 | $2.855 | $3.69 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:SPRY · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $2.96 | -0.73 | -19.8% | $3.28 | $3.465 | $2.855 | 2,784,259 | |
| $3.69 | +0.04 | +1.1% | $3.64 | $3.75 | $3.43 | 1,695,671 | |
| $3.65 | +0.06 | +1.7% | $3.52 | $3.785 | $3.52 | 1,191,124 | |
| $3.59 | -0.30 | -7.7% | $3.85 | $4.00 | $3.59 | 3,284,852 | |
| $3.89 | +0.08 | +2.1% | $3.86 | $3.995 | $3.79 | 1,297,321 | |
| $3.81 | -0.14 | -3.5% | $3.90 | $4.106 | $3.80 | 2,288,934 | |
| $3.95 | +0.38 | +10.6% | $3.57 | $4.13 | $3.57 | 3,845,251 | |
| $3.57 | +0.42 | +13.3% | $3.15 | $3.74 | $3.07 | 2,904,156 | |
| $3.15 | +0.36 | +12.9% | $2.81 | $3.17 | $2.73 | 3,185,284 | |
| $2.79 | +0.14 | +5.3% | $2.66 | $2.84 | $2.44 | 5,672,081 | |
| $2.65 | -0.40 | -13.1% | $3.05 | $3.095 | $2.60 | 2,768,593 | |
| $3.05 | 0.00 | 0.0% | $3.13 | $3.225 | $2.995 | 2,494,294 | |
| $3.05 | 0.00 | 0.0% | $3.05 | $3.11 | $2.92 | 2,422,127 | |
| $3.05 | -0.33 | -9.8% | $3.40 | $3.479 | $2.91 | 2,121,083 | |
| $3.38 | -0.28 | -7.7% | $3.62 | $3.79 | $3.34 | 1,754,250 | |
| $3.66 | +0.01 | +0.3% | $3.70 | $3.90 | $3.625 | 2,044,359 | |
| $3.65 | -0.08 | -2.1% | $3.66 | $3.73 | $3.525 | 2,534,720 | |
| $3.73 | -0.19 | -4.8% | $3.92 | $3.945 | $3.64 | 1,643,261 | |
| $3.92 | -0.11 | -2.7% | $4.03 | $4.09 | $3.90 | 1,433,829 | |
| $4.03 | -0.29 | -6.7% | $4.28 | $4.28 | $3.995 | 1,522,100 | |
| $4.32 | +0.14 | +3.3% | $4.13 | $4.355 | $4.13 | 1,786,600 | |
| $4.18 | -0.11 | -2.6% | $4.32 | $4.42 | $4.165 | 1,010,600 | |
| $4.29 | +0.06 | +1.4% | $4.25 | $4.44 | $4.225 | 1,542,700 | |
| $4.23 | +0.21 | +5.2% | $4.07 | $4.32 | $4.00 | 1,509,000 | |
| $4.02 | -0.05 | -1.2% | $4.08 | $4.08 | $3.81 | 2,332,000 | |
| $4.07 | +0.14 | +3.6% | $3.99 | $4.095 | $3.94 | 2,220,100 | |
| $3.93 | -0.12 | -3.0% | $4.01 | $4.095 | $3.885 | 1,728,800 | |
| $4.05 | -0.13 | -3.1% | $4.18 | $4.18 | $3.995 | 1,546,800 | |
| $4.18 | -0.05 | -1.2% | $4.20 | $4.27 | $4.06 | 1,274,300 | |
| $4.23 | -0.33 | -7.2% | $4.53 | $4.555 | $4.20 | 1,258,400 | |
| $4.56 | +0.20 | +4.6% | $4.35 | $4.635 | $4.21 | 1,584,900 | |
| $4.36 | +0.065 | +1.5% | $4.24 | $4.402 | $4.205 | 1,297,800 | |
| $4.295 | +0.005 | +0.1% | $4.31 | $4.31 | $4.08 | 1,219,200 | |
| $4.29 | +0.22 | +5.4% | $4.13 | $4.395 | $4.03 | 1,621,100 | |
| $4.07 | -0.05 | -1.2% | $4.16 | $4.27 | $3.985 | 1,828,500 | |
| $4.12 | -0.19 | -4.4% | $4.35 | $4.395 | $4.11 | 1,971,600 | |
| $4.31 | -0.09 | -2.0% | $4.43 | $4.45 | $4.24 | 1,297,400 | |
| $4.40 | +0.27 | +6.5% | $4.11 | $4.435 | $4.01 | 1,274,700 | |
| $4.13 | +0.05 | +1.2% | $4.06 | $4.19 | $4.00 | 949,800 | |
| $4.08 | -0.07 | -1.7% | $4.18 | $4.18 | $4.02 | 1,035,000 | |
| $4.15 | -0.03 | -0.7% | $4.21 | $4.24 | $4.07 | 1,052,600 | |
| $4.18 | -0.30 | -6.7% | $4.49 | $4.49 | $4.11 | 1,370,300 | |
| $4.48 | +0.13 | +3.0% | $4.40 | $4.57 | $4.36 | 1,268,000 | |
| $4.35 | +0.24 | +5.8% | $4.16 | $4.385 | $4.07 | 1,197,900 | |
| $4.11 | -0.04 | -1.0% | $4.10 | $4.20 | $4.10 | 1,885,800 | |
| $4.15 | -0.015 | -0.4% | $4.26 | $4.30 | $4.12 | 1,870,600 | |
| $4.165 | -0.085 | -2.0% | $4.25 | $4.365 | $4.125 | 1,451,900 | |
| $4.25 | -0.25 | -5.6% | $4.50 | $4.50 | $4.22 | 2,776,000 | |
| $4.50 | -0.26 | -5.5% | $4.80 | $4.90 | $4.455 | 2,165,300 | |
| $4.76 | -0.30 | -5.9% | $5.13 | $5.19 | $4.73 | 2,570,800 | |
| $5.06 | -0.17 | -3.3% | $5.20 | $5.22 | $5.02 | 1,091,300 | |
| $5.23 | -0.16 | -3.0% | $5.35 | $5.38 | $5.215 | 874,500 | |
| $5.39 | -0.23 | -4.1% | $5.515 | $5.535 | $5.305 | 1,086,500 | |
| $5.62 | -0.05 | -0.9% | $5.60 | $5.70 | $5.54 | 849,500 | |
| $5.67 | -0.15 | -2.6% | $5.86 | $5.90 | $5.605 | 1,088,200 | |
| $5.82 | +0.05 | +0.9% | $5.86 | $6.00 | $5.745 | 1,196,700 | |
| $5.77 | -0.23 | -3.8% | $6.08 | $6.08 | $5.74 | 1,358,000 | |
| $6.00 | +0.11 | +1.9% | $5.87 | $6.09 | $5.615 | 1,984,600 | |
| $5.89 | -0.14 | -2.3% | $6.00 | $6.03 | $5.855 | 1,190,300 | |
| $6.03 | 0.00 | 0.0% | $6.03 | $6.12 | $5.89 | 1,190,800 | |
| $6.03 | +0.31 | +5.4% | $5.70 | $6.09 | $5.67 | 1,162,100 | |
| $5.72 | +0.37 | +6.9% | $5.40 | $5.76 | $5.39 | 1,715,834 | |
| $5.35 | -0.155 | -2.8% | $5.40 | $5.46 | $5.20 | 1,936,733 | |
| $5.505 | 0.00 | 0.0% | $5.52 | $5.60 | $5.465 | 1,267,900 | |
| $5.505 | -0.875 | -13.7% | $6.30 | $6.35 | $5.50 | 2,114,100 |
- Ticker
- NASDAQ:SPRY
- Asset type
- Stock
- Sector
- Health care
- Industry
- Pharmaceuticals
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 5, 2026
ARS Pharma Reports Business Highlights and Third Quarter 2026 Financial Results
Latest earnings call · Nov 5, 2026
ARS Pharmaceuticals (NASDAQ:SPRY) Q3 2026 Earnings Call
Replay and transcript
Latest deck · May 15, 2026
Investor Presentation (May 2026)
Investor deck · 22 slides
Latest news
ARS Pharma Reports Business Highlights and Third Quarter 2026 Financial Results
Nov 5, 2026
Closed $2.79 (+5.3%) on Nov 6, 2026
ARS Pharma to Report Third Quarter 2026 Financial Results
Oct 28, 2026
Closed $3.66 (+0.3%) on Oct 29, 2026
ARS Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SPRY
Oct 5, 2026
Closed $4.29 (+5.4%) on Oct 5, 2026
ARS Pharmaceuticals Outlines Strategic Priorities, including a Focused Commercial Strategy, and Reports Second Quarter 2026 Financial Results
Aug 13, 2026
Closed $5.65 (-7.4%) on Aug 14, 2026
ARS Pharmaceuticals Announces Conference Call and Webcast on August 13 Outlining its Updated Strategic Priorities and Reporting Second Quarter 2026 Financial Results
Aug 3, 2026
Closed $5.46 (+6.4%) on Aug 3, 2026
ARS Pharmaceuticals Announces CEO Succession
Jul 7, 2026
Closed $8.10 (-1.1%) on Jul 8, 2026
ARS Pharmaceuticals Provides Commercial and Financial Updates
Jun 24, 2026
Closed $10.54 (+2.5%) on Jun 24, 2026
Drew Brees Collaborates with ARS Pharmaceuticals to Raise Awareness About Living Life with Severe Allergies
Jun 4, 2026
Closed $9.07 (+3.7%) on Jun 4, 2026
ARS Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Update
May 15, 2026
Closed $7.43 (-6.5%) on May 15, 2026
ARS Pharmaceuticals Strengthens Leadership Team with Appointment of Industry Veteran Donn Casale as President
May 13, 2026
Closed $8.01 (-7.2%) on May 13, 2026
ARS Pharmaceuticals, Inc. on 6ix
- Sector
- Health care
- Industry
- Pharmaceuticals
- News releases
- 23 in the last 12 months · 94 in all · newest Nov 5, 2026 · oldest 2023
- Calls
- 9 calls with a replay · 9 with a transcript · latest Nov 5, 2026
- Decks
- 20 decks · latest May 15, 2026
Where ARS Pharmaceuticals, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:SPRY · Home listing · This page | NASDAQ | United States | USD |
| BOATS:SPRY | BOATS | United States | USD |
Valuation
EV/sales 2.3× against a median of 2.6×: 6th lowest of 11 Pharmaceuticals companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $281.0M USD
- P/E
- Loss
- EV/sales
- 2.3×
- EV/EBITDA
- Negative EBITDA
- Price/book
- Negative equity
- Gross margin
- Not reported
- Operating margin
- −161.5%
- Net margin
- −163.6%
- Debt to equity
- Negative equity
- Beta vs S&P 500
- 2.09
Pharmaceuticals: the 10 companies nearest in size, of 492 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| ARS Pharmaceuticals, Inc. · NASDAQ:SPRY | US$297.6M | US$281.0M | n/a | 2.3× | n/a | n/a | −163.6% | n/a | 2.09 |
| Standard Chemical & Pharmaceutical Co. Ltd. · TWSE:1720 | US$316.1M | US$277.1M | 10.1× | 1.3× | 4.8× | 1.7× | 14.5% | 0.2× | n/a |
| Enwei Pharmaceutical Co., Ltd. Class A · SZSE:301331 | US$309.7M | US$266.0M | 54.6× | 2.1× | n/a | 2.0× | 4.6% | 0.2× | n/a |
| Ind-Swift Laboratories Ltd. · NSE:INDSWFTLAB | US$302.3M | US$263.1M | 33.5× | 3.2× | 23.7× | 1.9× | 11.1% | 0.0× | n/a |
| Hainan Huluwa Pharmaceutical Group Co. Ltd. Class A · SSE:605199 | US$287.7M | US$344.3M | n/a | 3.8× | n/a | 7.2× | −68.9% | 1.5× | n/a |
| Chengdu Huasun Technology Group Inc., Ltd. Class A · SZSE:000790 | US$285.5M | US$277.5M | n/a | 4.4× | n/a | 2.7× | −57.2% | 0.1× | n/a |
| Tiansheng Pharmaceutical Group Co. Ltd. Class A · SZSE:002872 | US$279.7M | US$239.5M | n/a | 3.1× | n/a | 1.0× | −10.6% | 0.0× | n/a |
| Bukwang Pharmaceutical Co., Ltd. · KRX:003000 | US$278.6M | US$153.0M | 42.7× | 1.0× | n/a | 1.1× | 4.1% | 0.0× | n/a |
| Ildong Pharmaceutical Co., Ltd. · KRX:249420 | US$277.9M | US$233.1M | 8.6× | 0.5× | 6.3× | 1.4× | 7.5% | 0.0× | n/a |
| Deva Holding A.S. · BIST:DEVA | US$276.9M | US$245.1M | n/a | 0.6× | 4.4× | 0.4× | −3.9% | 0.1× | n/a |
| Honz Pharmaceutical Co., Ltd. Class A · SZSE:300086 | US$276.0M | US$298.2M | n/a | 5.9× | n/a | 2.2× | −62.4% | 0.2× | n/a |
| Median of the others | US$282.6M | US$264.5M | 33.5× | 2.6× | 5.6× | 1.8× | 0.1% | 0.1× |
Forecasts
3 strong buy · 1 buy · Analysts' consensus from EODHD, read Nov 20, 2026. Not 6ix's view and not investment advice.
- Price target
- 17.00 USD · Analysts' mean
- EPS, year to Dec 2026
- -1.91 · 3 analysts
- Revenue, year to Dec 2026
- 120.4M · 4 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Donn Casale | President, Chief Executive Officer and Director |
| Kathleen Scott | Chief Financial Officer |
| Brian T. Dorsey | Chief Operating Officer |
| Alexander Fitzpatrick | Chief Legal Officer |
| John Slebir | Chief Legal Officer |
| Daniel Relovsky | Senior Vice President, Marketing |
| Lynda Harris | Vice President, Human Resources |
| Justin Chakma | Chief Business Officer |
| Meg Smith | Chief Commercial Officer |
| Randall Kaye | Chief Medical Officer |
Board
| Director | Role |
|---|---|
| Pratik Shah | Director and Chair of the Board |
| Brenton Saunders | Director |
| Donn Casale | President, Chief Executive Officer and Director |
| Laura Shawver | Director |
| Michael Kelly | Director |
| Peter A. Thompson | Director |
| Peter Kolchinsky | Director |
| Phillip Schneider | Director |
| Rajeev Dadoo | Director |
| Richard Lowenthal | Director |
| Saqib Islam | Director |
Events
Calls
| Call | When | Status |
|---|---|---|
| ARS Pharmaceuticals (NASDAQ:SPRY) Q3 2026 Earnings Call | Thu, Nov 05, 2026 · 4:30 PM ET | Replay |
| ARS Pharmaceuticals (NASDAQ:SPRY) Q2 2026 Earnings Call | Thu, Aug 13, 2026 · 4:30 PM ET | Replay |
| ARS Pharmaceuticals (NASDAQ:SPRY) Q1 2026 Earnings Call | Fri, May 15, 2026 · 8:30 AM ET | Replay |
| ARS Pharmaceuticals (NASDAQ:SPRY) Q4 2025 Earnings Call | Mon, Mar 09, 2026 · 8:30 AM ET | Replay |
| ARS Pharmaceuticals (NASDAQ:SPRY) Q3 2025 Earnings Call | Mon, Nov 10, 2025 · 8:30 AM ET | Replay |
| ARS Pharmaceuticals (NASDAQ:SPRY) Q2 2025 Earnings Call | Wed, Aug 13, 2025 · 8:30 AM ET | Replay |
| ARS Pharmaceuticals (NASDAQ:SPRY) Q1 2025 Earnings Call | Wed, May 14, 2025 · 8:30 AM ET | Replay |
| ARS Pharmaceuticals (NASDAQ:SPRY) Q4 2024 Earnings Call | Thu, Mar 20, 2025 · 8:30 AM ET | Replay |
| ARS Pharmaceuticals (NASDAQ:SPRY) Q3 2024 Earnings Call | Wed, Nov 13, 2024 · 8:00 AM ET | Replay |
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 5, 2026 · After close | +5.3% |
| Q2 2026 | Aug 13, 2026 · After close | −7.4% |
| Q1 2026 | May 15, 2026 · Before open | −6.5% |
| Q4 2025 | Mar 19, 2026 | −1.6% |
| Q3 2025 | Nov 10, 2025 · Before open | +0.3% |
| Q2 2025 | Aug 13, 2025 · Before open | −5.0% |
| Q1 2025 | May 14, 2025 · Before open | −9.4% |
| Q4 2024 | Mar 19, 2025 · Before open | +1.0% |
| Q3 2024 | Nov 13, 2024 · Before open | −15.2% |
| Q2 2024 | Aug 6, 2024 · After close | −2.2% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 9, 2024 · After close | −0.7% |
| Q4 2023 | Mar 21, 2024 · After close | −3.9% |
| Q3 2023 | Nov 9, 2023 · After close | +8.8% |
| Q2 2023 | Aug 10, 2023 · After close | −0.3% |
| Q1 2023 | May 15, 2023 · Before open | −2.9% |
| Q4 2022 | Mar 23, 2023 · After close | −4.0% |
| Q3 2022 | Nov 2, 2022 · After close | −2.7% |
| Q2 2022 | Aug 11, 2022 · After close | −1.9% |
| Q1 2022 | May 12, 2022 · After close | −2.3% |
| Q4 2021 | Mar 31, 2022 · After close | −8.6% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (May 2026) | Investor deck | 22 slides | May 15, 2026 |
| Q4 2025 Earnings Presentation | Earnings | 22 slides | Mar 9, 2026 |
| Investor Presentation (November 2025) | Investor deck | 19 slides | Nov 10, 2025 |
| Q3 2025 Earnings Presentation | Earnings | 10 slides | Nov 10, 2025 |
| Q2 2025 Earnings Presentation | Earnings | 18 slides | Aug 13, 2025 |
| 43rd Annual J.P. Morgan Healthcare Conference 2025 | Conference | 15 slides | Jan 13, 2025 |
| Corporate Update (August 2024) | Corporate update | 30 slides | Aug 12, 2024 |
| Investor Presentation (June 2024) | Investor deck | 32 slides | Jun 28, 2024 |
| Investor Presentation (June 2024) | Investor deck | 33 slides | Jun 28, 2024 |
| Investor Presentation (May 2024) | Investor deck | 41 slides | May 10, 2024 |
All 20 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Day (March 2024) | Investor day | 72 slides | Mar 7, 2024 |
| Investor Presentation (September 2023) | Investor deck | 17 slides | Sep 25, 2023 |
| Investor Presentation (May 2023) | Investor deck | 36 slides | May 16, 2023 |
| Investor Presentation (March 2023) | Investor deck | 41 slides | Mar 13, 2023 |
| Q1 2023 Earnings Presentation | Earnings | 26 slides | Feb 14, 2023 |
| Investor Presentation (December 2022) | Investor deck | 25 slides | December 2022 |
| Q4 2022 Earnings Presentation | Earnings | 28 slides | Nov 1, 2022 |
| Merger or Acquisition (July 2022) | Merger or acquisition | 33 slides | Jul 21, 2022 |
| Silverback Therapeutics — Corporate Update (March 2022) | Corporate update | 18 slides | Mar 31, 2022 |
| Silverback Therapeutics — Investor Presentation (September 2021) | Investor deck | 35 slides | Sep 16, 2021 |
IPO
Went public as Silverback Therapeutics, Inc. Priced at US$21.00 a share on Dec 3, 2020.
- Price
- US$21.00 a share
- Shares offered
- 11,500,000 shares of common stock
- Offering size
- US$241.5 million
- Underwriters' option
- Up to 1,725,000 more shares
- Underwriters
- Goldman Sachs & Co. LLC, SVB Leerink, Stifel, H.C. Wainwright & Co. · In the order on the cover
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Oct 2, 2020 |
| Filed publicly | Nov 10, 2020 |
| Amended twice | Newest Dec 3, 2020 |
| Shares registered with an exchange | Dec 1, 2020 |
| Declared effective by the SEC | Dec 3, 2020 |
| Final prospectus, with the price | Dec 4, 2020 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Dec 4, 2020 |
| EFFECT · Notice that a registration is effective | Dec 3, 2020 |
| S-1MEF · Registration of more shares for the same offering | Dec 3, 2020 |
| CERT · Exchange's certificate of listing | Dec 3, 2020 |
| S-1/A · Registration statement, amended | Dec 3, 2020 |
| CORRESP · Letter to the SEC | Dec 1, 2020 |
| CORRESP · Letter to the SEC | Dec 1, 2020 |
| 8-A12B · Registration of shares for listing on an exchange | Dec 1, 2020 |
| CORRESP · Letter to the SEC | Nov 30, 2020 |
| S-1/A · Registration statement, amended | Nov 30, 2020 |
All 16 filings
| Filing | Filed |
|---|---|
| UPLOAD · Letter from the SEC | Nov 27, 2020 |
| CORRESP · Letter to the SEC | Nov 18, 2020 |
| CORRESP · Letter to the SEC | Nov 10, 2020 |
| S-1 · Registration statement | Nov 10, 2020 |
| UPLOAD · Letter from the SEC | Oct 29, 2020 |
| DRS · Draft registration statement | Oct 2, 2020 |
Open IPO · From the cover of the final prospectus (424B4) filed Dec 4, 2020
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 84.3M | 89.1M | 30.0K | 1.32M | 5.51M | 17.8M | ||
| Cost of revenue | 20.4M | 20.6M | 0 | 17.1M | 213.0K | 14.1M | 1.55M | 1.42M |
| Gross profit | 63.9M | 68.6M | 30.0K | -15.8M | 5.29M | 3.77M | -1.55M | -1.42M |
| Research and development | 13.2M | 19.6M | 20.3M | 18.4M | 20.3M | 24.6M | 21.5M | 14.8M |
| Selling, general and administrative | 230.1M | 71.7M | 47.3M | 603.0K | 4.69M | 4.23M | ||
| Operating income | -179.4M | -3.08M | -67.5M | -35.5M | -19.5M | -32.9M | -24.1M | -18.3M |
| Depreciation and amortization | 1.37M | 79.0K | 100.0K | 100.0K | 213.0K | 637.0K | 1.55M | 1.42M |
| EBITDA | -178.1M | -3.00M | -67.4M | -35.4M | -19.2M | -32.3M | -22.5M | -16.9M |
| Interest expense | 2.60M | 0 | 834.0K | 106.0K | 29.0K | |||
| Income before tax | -171.4M | 8.29M | -54.4M | -34.7M | -20.2M | -1.06M | -24.0M | -17.6M |
| Income tax | -80.0K | 288.0K | 0 | 0 | 0 | 0 | ||
| Net income | -171.3M | 8.00M | -54.4M | -34.7M | -20.2M | -32.9M | -24.0M | -17.6M |
| Earnings per share, basic | -1.74 | 0.08 | -0.57 | -0.87 | -0.70 | -11.33 | -0.72 | -0.53 |
| Earnings per share, diluted | -1.74 | 0.08 | -0.57 | -0.87 | -0.70 | -11.33 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 41.3M | 50.8M | 71.0M | 210.5M | 60.1M | 386.6M | 9.98M | 20.2M |
| Short-term investments | 203.7M | 263.2M | 157.4M | 63.9M | 0 | |||
| Receivables | 25.3M | 8.18M | 0 | 1.01M | 1.00K | 384.0K | ||
| Inventory | 31.4M | 10.5M | 0 | -1.01M | -6.78M | -2.61M | ||
| Current assets | 284.9M | 334.3M | 231.7M | 277.7M | 60.7M | 390.7M | 10.5M | 20.8M |
| Property, plant and equipment | 2.46M | 1.07M | 574.0K | 329.0K | 72.0K | 1.62M | ||
| Total assets | 327.7M | 351.2M | 233.2M | 281.4M | 61.4M | 394.8M | 15.6M | 27.5M |
| Accounts payable | 5.72M | 9.87M | 759.0K | 1.66M | 1.79M | 2.58M | 3.52M | 775.0K |
| Current liabilities | 39.1M | 23.4M | 2.39M | 5.44M | 8.19M | 9.60M | 17.9M | 5.14M |
| Long-term debt | 96.4M | 4.93M | 7.46M | |||||
| Total debt | 96.4M | 0 | 274.0K | 481.0K | 9.03M | 10.0M | 15.6M | 7.73M |
| Total liabilities | 213.4M | 94.4M | 2.43M | 8.55M | 16.7M | 11.9M | 21.3M | 9.35M |
| Shareholders' equity | 114.3M | 256.8M | 230.8M | 272.9M | -31.3M | -14.1M | -5.60M | 18.2M |
| Shares outstanding | 99.3M | 98.0M | 96.4M | 93.9M | 30.4M | 34.7M | 33.1M | 33.1M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -170.9M | 13.5M | -59.3M | -40.1M | -17.6M | -31.2M | -18.9M | -16.9M |
| Capital spending | -339.0K | -563.0K | -175.0K | -199.0K | -55.0K | -917.0K | -96.0K | -449.0K |
| Free cash flow | -171.2M | 13.0M | -59.4M | -40.3M | -17.6M | -32.1M | -19.0M | -17.3M |
| Cash from investing | 56.8M | -106.1M | -87.2M | -199.0K | -55.0K | -917.0K | -96.0K | -449.0K |
| Cash from financing | 104.6M | 72.4M | 6.90M | 190.7M | 53.2M | 408.5M | 8.61M | 19.4M |
| Share buybacks | 570.0K | |||||||
| Change in cash | -9.50M | -20.2M | -139.5M | 150.5M | 35.5M | 14.2M | -10.2M | 2.08M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 144 · Notice of proposed sale | Nov 9, 2026 | Other filings | SEC |
| 10-Q · Quarterly report | Nov 5, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 5, 2026 | Results | SEC |
| 4 · Change in ownership | Nov 4, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Nov 4, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 30, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 19, 2026 | Other filings | SEC |
| 4 · Change in ownership | Oct 5, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 1, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 30, 2026 | Other filings | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 144 · Notice of proposed sale | Sep 11, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 11, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 4, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 3, 2026 | Other filings | SEC |
| 4 · Change in ownership | Sep 2, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 2, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 1, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 31, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 20, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 20, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 19, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 19, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 18, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 18, 2026 | Other filings | SEC |
| 3 · Initial statement of ownership | Aug 17, 2026 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 13, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 13, 2026 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Jul 27, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Jul 17, 2026 | Management or board change | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 14, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Jul 7, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Jul 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 25, 2026 | Meeting outcome | SEC |
| 4 · Change in ownership | Jun 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 12, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 12, 2026 | Other filings | SEC |
| 3 · Initial statement of ownership | Jun 1, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 15, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 15, 2026 | Results | SEC |
| 8-K · Current report | May 13, 2026 | Management or board change | SEC |
| ARS · Annual report to shareholders | Apr 29, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 29, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 29, 2026 | Meeting notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Apr 27, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Mar 31, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Mar 24, 2026 | Big-stake notice | SEC |
| S-8 · Registration statement for employee plans | Mar 9, 2026 | Offer document | SEC |
| 10-K · Annual report | Mar 9, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 9, 2026 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 13, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Jan 21, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 14, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 13, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 12, 2025 | Other filings | SEC |
| 144/A · Notice of proposed sale, amended | Nov 12, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 12, 2025 | Other filings | SEC |
| 10-Q · Quarterly report | Nov 10, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 10, 2025 | Results | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Oct 1, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Sep 29, 2025 | Material contract | SEC |
| 8-K · Current report | Aug 27, 2025 | Current report | SEC |
| 4 · Change in ownership | Aug 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 21, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 21, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 21, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 19, 2025 | Other filings | SEC |
| 10-Q · Quarterly report | Aug 13, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 13, 2025 | Results | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Aug 1, 2025 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jul 22, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jul 3, 2025 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jul 2, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jul 1, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jul 1, 2025 | Other filings | SEC |
| 4 · Change in ownership | Jun 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 27, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 26, 2025 | Meeting outcome | SEC |
| 4 · Change in ownership | Jun 20, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 18, 2025 | Other filings | SEC |
| 4 · Change in ownership | May 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 20, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | May 20, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | May 20, 2025 | Other filings | SEC |
| 10-Q · Quarterly report | May 14, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 14, 2025 | Results | SEC |
| 8-K · Current report | May 2, 2025 | Material contract | SEC |
| ARS · Annual report to shareholders | Apr 29, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 29, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 29, 2025 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 8, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Apr 7, 2025 | Other filings | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Mar 24, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Mar 21, 2025 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Mar 20, 2025 | Offer document | SEC |
| 144 · Notice of proposed sale | Mar 20, 2025 | Other filings | SEC |
| 10-K · Annual report | Mar 20, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 20, 2025 | Results | SEC |
| 4 · Change in ownership | Mar 7, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 5, 2025 | Other filings | SEC |
| 8-K · Current report | Mar 5, 2025 | Current report | SEC |
| 4 · Change in ownership | Feb 4, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 3, 2025 | Other filings | SEC |
| S-3ASR · Registration statement | Jan 31, 2025 | Offer document | SEC |
| 8-K · Current report | Jan 13, 2025 | Results | SEC |
| 4 · Change in ownership | Jan 7, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 6, 2025 | Other filings | SEC |
| 4 · Change in ownership | Jan 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 19, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 19, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 13, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 13, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 13, 2024 | Other filings | SEC |
| 4 · Change in ownership | Dec 12, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 12, 2024 | Other filings | SEC |
| 4 · Change in ownership | Dec 11, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 11, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 11, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 10, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 10, 2024 | Other filings | SEC |
| 4 · Change in ownership | Dec 9, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 9, 2024 | Insider trade | SEC |
| 144/A · Notice of proposed sale, amended | Dec 9, 2024 | Other filings | SEC |
| 4 · Change in ownership | Dec 6, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 6, 2024 | Other filings | SEC |
| 10-Q/A · Quarterly report, amended | Dec 6, 2024 | Quarterly report | SEC |
| 144 · Notice of proposed sale | Dec 5, 2024 | Other filings | SEC |
| 4 · Change in ownership | Dec 4, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 4, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 4, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 4, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 4, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 3, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 2, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 2, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 2, 2024 | Other filings | SEC |
| 4 · Change in ownership | Nov 27, 2024 | Insider trade | SEC |
| UPLOAD · Letter from the SEC | Nov 25, 2024 | Other filings | SEC |
| 4 · Change in ownership | Nov 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 21, 2024 | Insider trade | SEC |
| CORRESP · Letter to the SEC | Nov 18, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 15, 2024 | Other filings | SEC |
| 4 · Change in ownership | Nov 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 13, 2024 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 13, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 13, 2024 | Results | SEC |
| 8-K · Current report | Nov 12, 2024 | Material contract | SEC |
| UPLOAD · Letter from the SEC | Nov 7, 2024 | Other filings | SEC |
| 4 · Change in ownership | Oct 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 17, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 16, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 15, 2024 | Other filings | SEC |
| 8-K · Current report | Oct 15, 2024 | Material contract | SEC |
| 4 · Change in ownership | Oct 10, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 10, 2024 | Insider trade | SEC |
| 8-K · Current report | Sep 23, 2024 | Material contract | SEC |
| 4 · Change in ownership | Sep 19, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 19, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 19, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 18, 2024 | Other filings | SEC |
| 4 · Change in ownership | Sep 12, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 12, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 10, 2024 | Other filings | SEC |
This page holds 200 of 550 filings. Open Filings
Cap table
Built by 6ix from ARS Pharmaceuticals, Inc.’s releases · as of Nov 3, 2026
- Common shares
- 100,528,400
- Fully diluted
- 100,528,400
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 100,528,400 | Nov 3, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 3, 2026 | 100,528,400 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Peter Kolchinsky Other companies: Freenome, Inc. (Director · Since at least Jul 20, 2026); Parabilis Medicines, Inc. (Director · Since at least Jun 9, 2026); Hemab Therapeutics Holdings, Inc. (Director · Since at least Apr 30, 2026); SpyGlass Pharma, Inc. (Director · Since at least Feb 5, 2026); Evommune, Inc. (Director · Since at least Nov 5, 2025); Sionna Therapeutics, Inc. (Director · Since at least Feb 6, 2025); Septerna, Inc. (Director · Since at least Oct 24, 2024); Bicara Therapeutics Inc. (Director · Since at least Sep 12, 2024); Artiva Biotherapeutics, Inc. (Director · Since at least Jul 18, 2024); Cidara Therapeutics Inc (Director · Since at least Apr 24, 2024); LENZ Therapeutics, Inc. (Director · Since at least Mar 21, 2024); Mineralys Therapeutics, Inc. (Director · Since at least Feb 9, 2023); Acrivon Therapeutics, Inc. (Director · Since at least Nov 9, 2022); PepGen Inc. (Director · Since at least May 5, 2022); Nkarta, Inc. (Director · Since at least Feb 14, 2022); Tyra Biosciences, Inc. (Director · Since at least Sep 14, 2021); Climb Bio, Inc. (Director · Since at least Aug 9, 2021); Acumen Pharmaceuticals, Inc. (Director · Since at least Jun 30, 2021); Janux Therapeutics, Inc. (Director · Since at least Jun 10, 2021); Vor Biopharma Inc. (Director · Since at least Feb 4, 2021); 89bio Inc (Director · Since at least Nov 8, 2019); Wave Life Sciences Ltd. (Director · Since at least Aug 14, 2015); Black Diamond Therapeutics, Inc. (Director · Jul 5, 2023 – Jul 5, 2023 · Past); Iteos Therapeutics Inc (Director · Jun 9, 2022 – Jun 9, 2022 · Past); Icosavax Inc (Director · Jul 28, 2021 – Feb 19, 2024 · Past); Cytek Biosciences, Inc. (Director · Jul 22, 2021 – Mar 14, 2022 · Past); Jade Biosciences, Inc. (Director · Jun 29, 2021 – Jun 17, 2024 · Past); Werewolf Therapeutics, Inc. (Director · Apr 29, 2021 – May 12, 2025 · Past); Research Alliance Corp II (Chief Executive Officer, Director · Mar 17, 2021 – Mar 17, 2021 · Past); Orchard Therapeutics PLC (Director · Feb 9, 2021 – Feb 9, 2021 · Past); Solid Biosciences Inc. (Director · Dec 10, 2020 – Jan 11, 2024 · Past); POINT Biopharma Global Inc (Chief Executive Officer, Director · Jul 7, 2020 – Jun 29, 2021 · Past); Forma Therapeutics Holdings Inc (Director · Jun 18, 2020 – Jun 8, 2022 · Past); Satsuma Pharmaceuticals Inc (Director · Sep 12, 2019 – Jun 3, 2022 · Past); Synthorx Inc (Director · Dec 6, 2018 – Jan 23, 2020 · Past); Kala Bio, Inc. (Director · Oct 3, 2018 – Mar 13, 2020 · Past); Eidos Therapeutics Inc (Director · Jun 19, 2018 – Jun 19, 2018 · Past); KalVista Pharmaceuticals, Inc. (Director · Oct 12, 2017 – Oct 12, 2017 · Past); Ra Pharmaceuticals Inc (Director · Jun 20, 2017 – Apr 2, 2020 · Past); Dicerna Pharmaceuticals Inc (Director · Jan 29, 2014 – Nov 27, 2019 · Past) | Director · Since at least Nov 8, 2022 |
| Rajeev M Shah Other companies: Freenome, Inc. (Director · Since at least Jul 20, 2026); Parabilis Medicines, Inc. (Director · Since at least Jun 9, 2026); Hemab Therapeutics Holdings, Inc. (Director · Since at least Apr 30, 2026); SpyGlass Pharma, Inc. (Director · Since at least Feb 5, 2026); Evommune, Inc. (Director · Since at least Nov 5, 2025); Sionna Therapeutics, Inc. (Director · Since at least Feb 6, 2025); Septerna, Inc. (Director · Since at least Oct 24, 2024); Bicara Therapeutics Inc. (Director · Since at least Sep 12, 2024); Artiva Biotherapeutics, Inc. (Director · Since at least Jul 18, 2024); Cidara Therapeutics Inc (Director · Since at least Apr 24, 2024); LENZ Therapeutics, Inc. (Director · Since at least Mar 21, 2024); Mineralys Therapeutics, Inc. (Director · Since at least Feb 9, 2023); Acrivon Therapeutics, Inc. (Director · Since at least Nov 9, 2022); PepGen Inc. (Director · Since at least May 5, 2022); Nkarta, Inc. (Director · Since at least Feb 14, 2022); Tyra Biosciences, Inc. (Director · Since at least Sep 14, 2021); Wave Life Sciences Ltd. (Director · Since at least Aug 16, 2021); Climb Bio, Inc. (Director · Since at least Aug 9, 2021); Acumen Pharmaceuticals, Inc. (Director · Since at least Jun 30, 2021); Janux Therapeutics, Inc. (Director · Since at least Jun 10, 2021); Vor Biopharma Inc. (Director · Since at least Feb 4, 2021); 89bio Inc (Director · Since at least Nov 8, 2019); Iteos Therapeutics Inc (Director · Jun 9, 2022 – Jun 9, 2022 · Past); Forma Therapeutics Holdings Inc (Director · Jun 8, 2022 – Jun 8, 2022 · Past); Icosavax Inc (Director · Jul 28, 2021 – Feb 19, 2024 · Past); Cytek Biosciences, Inc. (Director · Jul 22, 2021 – Mar 14, 2022 · Past); Jade Biosciences, Inc. (Director · Jun 29, 2021 – Jun 17, 2024 · Past); POINT Biopharma Global Inc (Director · Jun 23, 2021 – Jun 29, 2021 · Past); Werewolf Therapeutics, Inc. (Director · Apr 29, 2021 – May 12, 2025 · Past); Orchard Therapeutics PLC (Director · Feb 9, 2021 – Feb 9, 2021 · Past); Black Diamond Therapeutics, Inc. (Director · Jan 29, 2020 – Jul 5, 2023 · Past); Satsuma Pharmaceuticals Inc (Director · Sep 12, 2019 – Jun 6, 2023 · Past); Eidos Therapeutics Inc (Director · Jun 19, 2018 – May 27, 2020 · Past); Solid Biosciences Inc. (Director · Jan 25, 2018 – Jan 11, 2024 · Past); Kala Bio, Inc. (Director · Jul 19, 2017 – Jun 17, 2021 · Past); KalVista Pharmaceuticals, Inc. (Director · Nov 21, 2016 – Oct 12, 2017 · Past); Ra Pharmaceuticals Inc (Director · Oct 25, 2016 – Apr 2, 2020 · Past) | Director · Since at least Nov 8, 2022 |
| James Flynn Other companies: Lite Strategy, Inc. (Non-Executive Director · Since at least Oct 31, 2023); Nuvalent, Inc. (Director · Since at least Jul 28, 2021); Larimar Therapeutics, Inc. (Director · Since at least May 28, 2020); Synlogic Inc (Director · Mar 19, 2024 – Apr 26, 2025 · Past); BiomX Inc. (Director · Mar 15, 2024 – Apr 21, 2025 · Past); RiceBran Technologies (Director · Jan 3, 2024 – Jan 3, 2024 · Past); Oruka Therapeutics, Inc. (Director · Dec 15, 2022 – Jan 30, 2024 · Past); CareMax Inc (Director · Nov 17, 2022 – Nov 17, 2023 · Past); Da32 Life Science Tech Acquisition Corp (Director · Jul 27, 2021 – Jul 28, 2023 · Past); Oncorus Inc (Director · Oct 1, 2020 – Feb 17, 2021 · Past); Acutus Medical Inc. (Director · Aug 5, 2020 – Jan 27, 2025 · Past); Deerfield Healthcare Technology Acquisitions Corp (Director · Jul 16, 2020 – Jul 21, 2020 · Past); Q32 Bio Inc. (Director · Mar 27, 2018 – Jun 6, 2019 · Past); AdaptHealth Corp. (Director · Feb 15, 2018 – Nov 8, 2019 · Past); Alpine Immune Sciences Inc (Director · Sep 12, 2016 – Sep 12, 2016 · Past); AveXis Inc (Director · Sep 3, 2015 – Feb 10, 2016 · Past) | Director · Nov 8, 2022 – Nov 8, 2022 · Past |
| Peter Thompson Other companies: Aspen Neuroscience, Inc. (General Partner · Since at least Nov 2, 2026); Sionna Therapeutics, Inc. (Director · Since at least Feb 6, 2025); Edgewise Therapeutics, Inc. (Chairman and Co-Founder · Since at least Mar 25, 2021); Corvus Pharmaceuticals, Inc. (CO-FOUNDER · Since at least Mar 22, 2016); Janux Therapeutics, Inc. (Director · Jun 10, 2021 – Jun 14, 2022 · Past); Decibel Therapeutics Inc (Director · Feb 11, 2021 – Jun 17, 2022 · Past); PMV Pharmaceuticals, Inc. (Director · Sep 24, 2020 – Jun 2, 2021 · Past); Prevail Therapeutics Inc (Director · Jun 19, 2019 – Jan 22, 2021 · Past); Synthorx Inc (Director · Dec 6, 2018 – Jan 23, 2020 · Past); Principia Biopharma Inc (Director · Sep 13, 2018 – Sep 13, 2018 · Past); Alpine Immune Sciences Inc (Director · Jul 24, 2017 – May 18, 2024 · Past); Adaptimmune Therapeutics PLC (Director · Jan 1, 2016 – Jun 4, 2018 · Past); Sierra Oncology Inc (Director · Jul 15, 2015 – Jul 21, 2015 · Past); Anthera Pharmaceuticals Inc (Director · Feb 1, 2011 – May 8, 2012 · Past); Trubion Pharmaceuticals Inc (President and CEO, Director · Oct 17, 2006 – Aug 27, 2009 · Past) | Director · Since at least Dec 3, 2020 |
| Vickie Capps Other companies: Orthofix Medical Inc. (Director · Since at least Mar 11, 2025); Janux Therapeutics, Inc. (Director · Since at least Jun 10, 2021); Amedisys Inc (Director · Since at least Nov 1, 2019); Synthorx Inc (Director · Dec 6, 2018 – Jan 23, 2020 · Past); NuVasive Inc (Director · Jun 12, 2015 – Sep 1, 2023 · Past); Connecture Inc (Director · Dec 11, 2014 – Apr 25, 2018 · Past); Otonomy Inc (Director · Aug 12, 2014 – Nov 28, 2022 · Past); Senorx Inc (Director · Jun 14, 2007 – Feb 26, 2010 · Past); Djo Inc (Executive VP, CFO · Jun 28, 2006 – Nov 20, 2007 · Past) | Director · Dec 3, 2020 – Jun 10, 2022 · Past |
| Robert Hershberg Other companies: Danaher Corporation (Director · Since at least Nov 15, 2026); AtaiBeckley Inc. (Director · Since at least Jun 4, 2026); Hillevax Inc (President and CEO, Director · Since at least Apr 28, 2022); Recursion Pharmaceuticals, Inc. (Board Member · Since at least Apr 15, 2021); Adaptive Biotechnologies Corporation (Board Member · Since at least Jun 26, 2019); Fate Therapeutics, Inc. (Director · May 1, 2020 – Jun 6, 2023 · Past); NanoString Technologies Inc (Director · Mar 2, 2015 – Apr 18, 2022 · Past); Dendreon Corp (Sr. VP & Chief Medical Officer · Dec 31, 2005 – Jan 19, 2006 · Past) | Director · Dec 3, 2020 – Jun 10, 2022 · Past |
| Brent Saunders Other companies: Bausch + Lomb Corporation (Chairman of the Board and CEO, Director · Since at least Mar 6, 2023); SkinHealth Systems Inc. (Chairman · Since at least Sep 29, 2020); BridgeBio Pharma, Inc. (Director · Jun 23, 2020 – Jun 22, 2022 · Past); Cisco Systems, Inc. (Director · Mar 13, 2017 – Dec 8, 2022 · Past); Forest Laboratories Inc (CEO & President, Director · Aug 23, 2011 – Jun 30, 2014 · Past); Merck & Company, Inc. (Senior Vice President · May 19, 2006 – Nov 3, 2009 · Past) | Director · Since at least Nov 8, 2022 |
| Jonathan Leff Other companies: Larimar Therapeutics, Inc. (Director · Since at least May 28, 2020); BiomX Inc. (Director · Mar 15, 2024 – Apr 14, 2025 · Past); Protara Therapeutics, Inc. (Director · Aug 2, 2017 – Jun 8, 2018 · Past); AveXis Inc (Director · Feb 10, 2016 – Feb 10, 2016 · Past); Alpine Immune Sciences Inc (Director · Jun 16, 2015 – Sep 11, 2015 · Past); InterMune Inc (EVP, Research & Development · Feb 27, 2012 – Sep 29, 2014 · Past) | Director · Nov 8, 2022 – Nov 8, 2022 · Past |
| Jonathan Root Other companies: Carlsmed, Inc. (Chair of the Nominating and Corporate Governance Committee · Since at least Jul 22, 2025); Omada Health, Inc. (Director · Since at least Jun 5, 2025); Edgewise Therapeutics, Inc. (Director · Since at least Mar 25, 2021); eFFECTOR Therapeutics Inc (Director · Aug 25, 2021 – Dec 2, 2021 · Past); Inari Medical Inc (Director · May 21, 2020 – Feb 19, 2025 · Past); OncoMed Pharmaceuticals Inc (Director · Jul 17, 2013 – Apr 23, 2019 · Past) | Director · Dec 3, 2020 – Jun 10, 2022 · Past |
| Phillip Schneider Other companies: Longboard Pharmaceuticals Inc (Director · Mar 11, 2021 – Dec 2, 2024 · Past); Pfenex Inc (Director · Jul 24, 2014 – Oct 1, 2020 · Past); Auspex Pharmaceuticals Inc (Director · Feb 4, 2014 – May 5, 2015 · Past); Arena Pharmaceuticals Inc (Director · Dec 11, 2007 – Jun 13, 2017 · Past) | Director · Since at least Nov 8, 2022 |
All 38 people
| Person | Seat |
|---|---|
| Alexander Fitzpatrick Other companies: Evofem Biosciences, Inc. (General Counsel and Secretary · Jan 17, 2018 – Feb 18, 2022 · Past); Verenium Corp (Sr. VP & General Counsel · Nov 8, 2010 – Oct 31, 2013 · Past); Kintera Inc (SVP and General Counsel · May 2, 2007 – Jul 8, 2008 · Past) | Chief Legal Officer · Since at least Dec 1, 2022 |
| Andrew Kenneth William Powell Other companies: Synthorx Inc (Director · Dec 19, 2018 – Jan 23, 2020 · Past); Lifecore Biomedical, Inc. (Director · Oct 12, 2018 – Jun 4, 2022 · Past); Aclaris Therapeutics, Inc. (Director · May 16, 2018 – Jun 1, 2024 · Past) | Director · Dec 3, 2020 – Jun 10, 2022 · Past |
| Brian T. Dorsey Other companies: Apricus Biosciences Inc (SVP, Chief Development Officer · Dec 1, 2014 – Jan 1, 2018 · Past); Pernix Therapeutics Holdings Inc (SVP Research · Apr 19, 2013 – Oct 10, 2014 · Past); Somaxon Pharmaceuticals Inc (SVP, Technical Operations · Nov 9, 2006 – Dec 31, 2012 · Past) | Chief Operating Officer · Since at least Dec 6, 2022 |
| Kathleen Scott Other companies: Dermata Therapeutics, Inc. (Director · Since at least Aug 12, 2021); NKGen Biotech Inc. (Director · Sep 29, 2023 – Dec 6, 2024 · Past); Histogen Inc (Director · Nov 18, 2019 – Nov 18, 2019 · Past) | Chief Financial Officer · Since at least Nov 8, 2022 |
| Laura Shawver Other companies: Relay Therapeutics, Inc. (Director · Jul 15, 2020 – Jun 3, 2024 · Past); Nkarta, Inc. (Director · Jul 9, 2020 – Jun 8, 2022 · Past); Synthorx Inc (President and CEO, Director · Dec 6, 2018 – Jan 23, 2020 · Past) | Director · Since at least Dec 3, 2020 |
| Randall Kaye Other companies: Longboard Pharmaceuticals Inc (Executive Vice President & CMO · Mar 21, 2022 – Dec 2, 2024 · Past); Axsome Therapeutics, Inc. (Chief Medical Officer · Nov 19, 2015 – Dec 23, 2015 · Past); Avanir Pharmaceuticals Inc (Sr. VP, Chief Medical Officer · Jan 16, 2006 – Sep 9, 2011 · Past) | Chief Medical Officer · Since at least Nov 5, 2026 |
| Thilo Schroeder Other companies: PMV Pharmaceuticals, Inc. (Director · Sep 24, 2020 – Oct 6, 2021 · Past); Revolution Medicines, Inc. (Director · Feb 12, 2020 – Dec 5, 2024 · Past); IDEAYA Biosciences, Inc. (Director · May 22, 2019 – May 22, 2019 · Past) | Director · Dec 3, 2020 – Dec 8, 2020 · Past |
| Maria Koehler Other companies: ImageneBio, Inc. (Director · Apr 15, 2021 – Jun 7, 2024 · Past); Repare Therapeutics Inc (EVP, CHIEF MEDICAL OFFICER · Jun 18, 2020 – Mar 12, 2025 · Past) | Director · Mar 12, 2021 – Jun 10, 2022 · Past |
| Pratik Shah Other companies: Design Therapeutics, Inc. (Co-Founder, President, CEO and Chairperson · Since at least Mar 25, 2021); Synthorx Inc (Director · Dec 6, 2018 – Jan 23, 2020 · Past) | Director and Chair of the Board · Since at least Nov 8, 2022 |
| Saqib Islam Other companies: Passage Bio, Inc. (Director · Since at least May 27, 2021); SpringWorks Therapeutics Inc (Chief Executive Officer, Director · Since at least Jan 7, 2021) | Director · Since at least Dec 3, 2020 |
| Michael Kelly Other companies: Hemab Therapeutics Holdings, Inc. (Vice President, Clinical Development · Since at least Nov 5, 2026) | Director · Since at least Nov 8, 2022 |
| Valerie Odegard Other companies: Odyssey Therapeutics, Inc. (Director · Since at least May 7, 2026) | President and CSO · Dec 3, 2020 – May 2, 2022 · Past |
| Brenton Saunders | Director · Since at least Nov 5, 2026 |
| Daniel Relovsky | Senior Vice President, Marketing · Since at least Nov 5, 2026 |
| Donn Casale | President, Chief Executive Officer and Director · Since at least Jun 1, 2026 |
| Eric Karas | Chief Commercial Officer · Since at least Nov 8, 2022 |
| Jeffrey C Pepe | Interim CEO and GC · Sep 2, 2022 – Sep 2, 2022 · Past |
| John Slebir | Chief Legal Officer · Since at least Nov 5, 2026 |
| Jonathan Piazza | Chief Financial Officer · Dec 3, 2020 – May 2, 2022 · Past |
| Justin Chakma | Chief Business Officer · Since at least Nov 8, 2022 |
| Lynda Harris | Vice President, Human Resources · Since at least Nov 5, 2026 |
| Margaret Ekins Smith | Chief Commercial Officer · Since at least Aug 17, 2026 |
| Meg Smith | Chief Commercial Officer · Since at least Aug 13, 2026 |
| Naomi Hunder | Chief Medical Officer · Dec 3, 2020 – May 2, 2022 · Past |
| Rajeev Dadoo | Director · Since at least Nov 8, 2022 |
| Richard Lowenthal | Director · Since at least Nov 8, 2022 |
| Russ Hawkinson | Sr. Vice President of Finance · Dec 3, 2020 – May 2, 2022 · Past |
| Sarina Tanimoto | CHIEF MEDICAL OFFICER · Since at least Nov 8, 2022 |
Log in to ask 6ix AI your own questions about ARS Pharmaceuticals, Inc.